Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epigenetics-Based Therapeutics for Neurodegenerative Disorders.

Literature DB >> 23526405

Epigenetics-Based Therapeutics for Neurodegenerative Disorders.

Abstract

Epigenetic regulation, such as DNA methylation and histone modification, is implicated in the aberrant changes in gene expression that occur during the progression of neurodegeneration. Many epigenetics-based drugs have been developed recently for the treatment of some neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's diseases. Here we review recent studies that highlight the role of epigenetic modifications in neurodegeneration, among them DNA methylation and demethylation and histone acetylation and deacetylation; we also explore the possibility of using epigenetics-based therapeutics to treat neurodegenerative disorders.

Entities: Chemical Disease Gene Mutation Species

Keywords: Alzheimer’s disease; Amyotrophic lateral sclerosis; DNA demethylation; DNA methylation; DNMT inhibitors; HDAC inhibitors; Histone acetylation; Huntington’s disease; Neurodegeneration; Parkinson’s disease; Therapeutics

Year: 2012 PMID： 23526405 PMCID： PMC3601938 DOI： 10.1007/s13670-012-0027-0

Source DB: PubMed Journal: Curr Transl Geriatr Exp Gerontol Rep ISSN： 2162-4941

63 in total

Review 1. Epigenetic modifications and human disease.

Authors: Anna Portela; Manel Esteller
Journal: Nat Biotechnol Date: 2010-10 Impact factor: 54.908

2. MBD family proteins: reading the epigenetic code.

Authors: Mehrnaz Fatemi; Paul A Wade
Journal: J Cell Sci Date: 2006-08-01 Impact factor: 5.285

3. Alteration of familial ALS-linked mutant SOD1 solubility with disease progression: its modulation by the proteasome and Hsp70.

Authors: Shingo Koyama; Shigeki Arawaka; Ren Chang-Hong; Manabu Wada; Toru Kawanami; Keiji Kurita; Masaaki Kato; Makiko Nagai; Masashi Aoki; Yasuto Itoyama; Gen Sobue; Pak H Chan; Takeo Kato
Journal: Biochem Biophys Res Commun Date: 2006-03-09 Impact factor: 3.575

Review 4. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors: Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal: Hum Mol Genet Date: 2010-04-15 Impact factor: 6.150

5. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors: J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal: Nature Date: 2001-10-18 Impact factor: 49.962

Review 6. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.

Authors: Ted Abel; R Suzanne Zukin
Journal: Curr Opin Pharmacol Date: 2008-02 Impact factor: 5.547

7. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line.

Authors: Ryuichi Kohno; Hideyuki Sawada; Yasuhiro Kawamoto; Kengo Uemura; Hiroshi Shibasaki; Shun Shimohama
Journal: Biochem Biophys Res Commun Date: 2004-05-21 Impact factor: 3.575

8. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.

Authors: Judit Pallos; Laszlo Bodai; Tamas Lukacsovich; Judith M Purcell; Joan S Steffan; Leslie Michels Thompson; J Lawrence Marsh
Journal: Hum Mol Genet Date: 2008-09-01 Impact factor: 6.150

9. Chromosomal profiles of gene expression in Huntington's disease.

Authors: Alexander N Anderson; Federico Roncaroli; Angela Hodges; Manuel Deprez; Federico E Turkheimer
Journal: Brain Date: 2007-12-21 Impact factor: 13.501

10. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration.

Authors: Claire L Simpson; Robin Lemmens; Katarzyna Miskiewicz; Wendy J Broom; Valerie K Hansen; Paul W J van Vught; John E Landers; Peter Sapp; Ludo Van Den Bosch; Joanne Knight; Benjamin M Neale; Martin R Turner; Jan H Veldink; Roel A Ophoff; Vineeta B Tripathi; Ana Beleza; Meera N Shah; Petroula Proitsi; Annelies Van Hoecke; Peter Carmeliet; H Robert Horvitz; P Nigel Leigh; Christopher E Shaw; Leonard H van den Berg; Pak C Sham; John F Powell; Patrik Verstreken; Robert H Brown; Wim Robberecht; Ammar Al-Chalabi
Journal: Hum Mol Genet Date: 2008-11-07 Impact factor: 6.150

9 in total

1. Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.

Authors: Louise M Collins; Luc J Adriaanse; Surabhi D Theratile; Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal: Mol Neurobiol Date: 2014-07-29 Impact factor: 5.590

Review 2. Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.

Authors: Navneet Ammal Kaidery; Shaista Tarannum; Bobby Thomas
Journal: Neurotherapeutics Date: 2013-10 Impact factor: 7.620

3. Anti-Amnesic Effect of Fermented Ganoderma lucidum Water Extracts by Lactic Acid Bacteria on Scopolamine-Induced Memory Impairment in Rats.

Authors: Yu Jin Choi; Hee Sun Yang; Jun Hee Jo; Sang Cheon Lee; Tae Young Park; Bong Suk Choi; Kyoung Sun Seo; Chang Ki Huh
Journal: Prev Nutr Food Sci Date: 2015-06-30

4. Blood transcriptomics of drug-naïve sporadic Parkinson's disease patients.

Authors: Raffaella Calligaris; Mihaela Banica; Paola Roncaglia; Elisa Robotti; Sara Finaurini; Christina Vlachouli; Lucia Antonutti; Francesco Iorio; Annamaria Carissimo; Tatiana Cattaruzza; Andrea Ceiner; Dejan Lazarevic; Alberto Cucca; Nicola Pangher; Emilio Marengo; Diego di Bernardo; Gilberto Pizzolato; Stefano Gustincich
Journal: BMC Genomics Date: 2015-10-28 Impact factor: 3.969